Annexon, Inc. - common stock (NQ:ANNX)

5.025 -0.195 (-3.74%)

Streaming Delayed Price Updated: 3:24 PM EST, Jan 6, 2026 Add to My Watchlist

Price and Volume

Volume	2,010,849
Open	5.170
Bid (Size)	5.020 (1,600)
Ask (Size)	5.030 (2,400)
Prev. Close	5.220
Today's Range	4.950 - 5.170
52wk Range	1.285 - 5.480
Shares Outstanding	47,722,995
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

December 16, 2025

From Annexon Biosciences

Via GlobeNewswire

Which stocks are moving on Wednesday? ↗

November 19, 2025

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Performance

YTD	+7.1%	+7.1%
1 Month	+3.4%	+3.4%
3 Month	+58.0%	+58.0%
6 Month	+84.1%	+84.1%
1 Year	-0.5%	-0.5%

More News

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 19, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 14, 2025

Via Benzinga

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

November 14, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

November 10, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Biosciences to Participate in Upcoming September Investor Conferences

August 27, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Narrows Loss in Fiscal Q2 ↗

August 14, 2025

Via The Motley Fool

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

August 14, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

August 07, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

July 24, 2025

From Annexon Biosciences

Via GlobeNewswire

Thursday's session: gap up and gap down stocks ↗

July 10, 2025

Via Chartmill

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

June 18, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025

From Annexon Biosciences

Via GlobeNewswire

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 14, 2025

Via Benzinga

Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

May 13, 2025

Via Benzinga

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 09, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 07, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

April 16, 2025

From Annexon Biosciences

Via GlobeNewswire

Frequently Asked Questions

Is Annexon, Inc. - common stock publicly traded?

Yes, Annexon, Inc. - common stock is publicly traded.

What exchange does Annexon, Inc. - common stock trade on?

Annexon, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Annexon, Inc. - common stock?

The ticker symbol for Annexon, Inc. - common stock is ANNX on the Nasdaq Stock Market

What is the current price of Annexon, Inc. - common stock?

The current price of Annexon, Inc. - common stock is 5.025

When was Annexon, Inc. - common stock last traded?

The last trade of Annexon, Inc. - common stock was at 01/06/26 03:24 PM ET

What is the market capitalization of Annexon, Inc. - common stock?

The market capitalization of Annexon, Inc. - common stock is 239.81M

How many shares of Annexon, Inc. - common stock are outstanding?

Annexon, Inc. - common stock has 240M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.